Who should attend
Executive Education Courses are taught to the School's high standard and are therefore academically rigorous. Participants are expected to be fluent in English, with a good undergraduate degree in a relevant subject.
The Market Access Academy is tailored towards access new starters. Our target participant profile is an individual who meets the following criteria:
- Minimum of five years’ experience post-university.
- Leadership experience in other functions, with a look to gain Access exposure.
- Limited/or very specific Access experience, which lacks the broader view.
- Recently became (<1 year), or will become, Global Access Leads in the near future.
- Fluency in English
About the course
Created in collaboration with The Boston Consulting Group (BCG) and leading pharmaceutical companies from around the world, this intensive course connects pharmaceutical management with advanced knowledge and strategies in market access.
The Market Access Academy is aimed at present and future Access Leaders within the pharmaceutical industry. Based on key business needs, it will provide participants with a common grounding in market access, training in representative decision-making across the product life-cycle, and strategies to adapt to a rapidly changing industry landscape.
We have a highly developed programme of lectures, case studies, workshops, and notable guest speakers. This bespoke selection provides technical experts - as well as those from other functions - the tools to understand the market access environment, plan strategy, and optimise access and value.
What will Access Leaders gain?
- A common grounding in market access.
- Training in representative decision-making across the product life-cycle.
- Strategies to adapt to a changing landscape.
- Five days of lectures, case studies, workshops and VIP guest speakers.
The Academy is taught over five days and is a mix of lectures, panel speakers, and interactive case studies:
Module 1: Understanding access, drivers, and barriers
Learning objectives: Understanding of key leverage points (evidence, non-evidence) used to optimise P&R outcomes across different in-scope markets and TAs.
Module 2: Defining an integrated evidence package
Learning objectives: Navigating challenges and trade-offs (internal and external) for successful decision-making in evidence-generation planning and synthesis.
Module 3: Creating a receptive access environment
Learning objectives: Identifying key relevant stakeholders and assessing different non-evidence access levers enabling Access Leaders to develop a broader stakeholder engagement plan beyond HTAs and payers. This module focuses on the importance of market access stakeholders, the role of patient organisations, and utilising collaborative negotiations to realise success.
Module 4: Optimising access and value
Learning objectives: Developing a successful strategic P&R approach by understanding the overall option space, trade-offs and most relevant tools. The module provides participants with the technical functional expertise needed to develop P&R strategies and then expands on how to build an effective pricing strategy in three parts, with focus on the payer and industry perspectives.
Module 5: Managing access strategy and execution
Learning objectives: Understanding the behaviours and tools of successful cross-functional Access Leaders, as seen by executives and senior internal clients.
During the course's highly interactive five days, participants will:
- Learn representative decision-making as Access Leaders, including how to frame and address business requirements/issues.
- Understand the functional, technical access competencies (policy, evidence generation etc.) and the roles they play in business decisions.
- Deepen understanding of evolving access-relevant trends and access landscape/environment.
- Network with pharmaceutical executives, industry professionals from Health Technology Assessment (HTA) bodies, key policy makers and more
Elias Mossialos is Brian Abel-Smith Professor of Health Policy, Head of Department of Health Policy and Director of LSE Health. Professor Mossialos founded LSE Health in 1996. It is currently LSE's largest research centre with 60 staff working on a wide range of research, combining technical comp...
Dr Panos Kanavos is Associate Professor of International Health Policy in the Department of Health Policy at London School of Economics and Political Science, Deputy Director at LSE Health and Programme Director of the Medical Technology Research Group (MTRG). Dr Kanavos has previously been Hark...
Professor Alistair McGuire is Chair of Health Economics in the Department of Health Policy. Prior to this he was Professor of Economics at City University, London after being a tutor in Economics at the University of Oxford. Professor McGuire has also been a Visiting Professor at Harvard Universi...
Allan Hackshaw has more than 23 years' experience in clinical research and academic teaching. He has worked in a variety of disciplines (prevention, detection, treatment and laboratory experiments) on a range of medical disorders. He has been key investigator on successful grant applications with...
Videos and materials
Read more about Negotiations
Because of COVID-19, many providers are cancelling or postponing in-person programs or providing online participation options.
We are happy to help you find a suitable online alternative.